Literature DB >> 35286532

Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT.

Haotian Liao1, Hanyu Jiang2, Yuntian Chen2, Ting Duan2, Ting Yang2, Miaofei Han3, Zhong Xue3, Feng Shi3, Kefei Yuan1, Mustafa R Bashir4, Dinggang Shen5,6, Bin Song7, Yong Zeng8.   

Abstract

BACKGROUND: Exploring the genomic landscape of hepatocellular carcinoma (HCC) provides clues for therapeutic decision-making. Phosphatidylinositol-3 kinase (PI3K) signaling is one of the key pathways regulating HCC aggressiveness, and its genomic alterations have been correlated with sorafenib response. In this study, we aimed to predict somatic mutations of the PI3K signaling pathway in HCC samples through machine-learning-based radiomic analysis.
METHODS: HCC patients who underwent next-generation sequencing and preoperative contrast-enhanced CT were recruited from West China Hospital and The Cancer Genome Atlas for model training and validation, respectively. Radiomic features were extracted from volumes of interest (VOIs) covering the tumor (VOItumor) and peritumoral areas (5 mm [VOI5mm], 10 mm [VOI10mm], and 20 mm [VOI20mm] from tumor margin). Factor analysis, logistic regression analysis, least absolute shrinkage and selection operator, and random forest analysis were applied for feature selection and model construction. Model performance was characterized based on the area under the receiver operating characteristic curve (AUC).
RESULTS: A total of 132 HCC patients (mean age: 61.1 ± 14.7 years; 108 men) were enrolled. In the training set, the AUCs of radiomic signatures based on single CT phases were moderate (AUC 0.694-0.771). In the external validation set, the radiomic signature based on VOI10mm in arterial phase demonstrated the highest AUC (0.733) among all models. No improvement in model performance was achieved after adding the tumor radiomic features or manually assessed qualitative features.
CONCLUSIONS: Machine-learning-based radiomic analysis had potential for characterizing alterations of PI3K signaling in HCC and could help identify potential candidates for sorafenib treatment.
© 2022. Society of Surgical Oncology.

Entities:  

Year:  2022        PMID: 35286532     DOI: 10.1245/s10434-022-11505-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  43 in total

1.  Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.

Authors:  Daniela Sia; Yang Jiao; Iris Martinez-Quetglas; Olga Kuchuk; Carlos Villacorta-Martin; Manuel Castro de Moura; Juan Putra; Genis Camprecios; Laia Bassaganyas; Nicholas Akers; Bojan Losic; Samuel Waxman; Swan N Thung; Vincenzo Mazzaferro; Manel Esteller; Scott L Friedman; Myron Schwartz; Augusto Villanueva; Josep M Llovet
Journal:  Gastroenterology       Date:  2017-06-15       Impact factor: 22.682

Review 2.  Hepatocellular carcinoma.

Authors:  Josep M Llovet; Robin Kate Kelley; Augusto Villanueva; Amit G Singal; Eli Pikarsky; Sasan Roayaie; Riccardo Lencioni; Kazuhiko Koike; Jessica Zucman-Rossi; Richard S Finn
Journal:  Nat Rev Dis Primers       Date:  2021-01-21       Impact factor: 52.329

3.  Global cancer statistics, 2012.

Authors:  Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2015-02-04       Impact factor: 508.702

Review 4.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations.

Authors:  Jeffrey A Engelman
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

5.  Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States.

Authors:  Sean F Altekruse; S Jane Henley; James E Cucinelli; Katherine A McGlynn
Journal:  Am J Gastroenterol       Date:  2014-02-11       Impact factor: 10.864

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma.

Authors:  Erin Bresnahan; Pedro Molina-Sánchez; Katherine E Lindblad; Barbara Maier; Marina Ruiz de Galarreta; Daniela Sia; Marc Puigvehi; Verónica Miguela; María Casanova-Acebes; Maxime Dhainaut; Carlos Villacorta-Martin; Aatur D Singhi; Akshata Moghe; Johann von Felden; Lauren Tal Grinspan; Shuang Wang; Alice O Kamphorst; Satdarshan P Monga; Brian D Brown; Augusto Villanueva; Josep M Llovet; Miriam Merad; Amaia Lujambio
Journal:  Cancer Discov       Date:  2019-06-11       Impact factor: 39.397

8.  Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Authors:  Nicole Grabinski; Florian Ewald; Bianca T Hofmann; Katharina Staufer; Udo Schumacher; Björn Nashan; Manfred Jücker
Journal:  Mol Cancer       Date:  2012-11-20       Impact factor: 27.401

9.  Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies.

Authors:  Nikolaus Schultz; Ghassan K Abou-Alfa; James J Harding; Subhiksha Nandakumar; Joshua Armenia; Danny N Khalil; Melanie Albano; Michele Ly; Jinru Shia; Jaclyn F Hechtman; Ritika Kundra; Imane El Dika; Richard K Do; Yichao Sun; T Peter Kingham; Michael I D'Angelica; Michael F Berger; David M Hyman; William Jarnagin; David S Klimstra; Yelena Y Janjigian; David B Solit
Journal:  Clin Cancer Res       Date:  2018-10-29       Impact factor: 12.531

Review 10.  The biology of Hepatocellular carcinoma: implications for genomic and immune therapies.

Authors:  Galina Khemlina; Sadakatsu Ikeda; Razelle Kurzrock
Journal:  Mol Cancer       Date:  2017-08-30       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.